444582-88-1

Usage

Properties

A piperazine derivative with a 1,1-dimethylethyl ester group and a phenylmethoxyphenyl moiety
Potential pharmaceutical applications
May have biological activity due to its structure
Could be used as an intermediate in the synthesis of pharmaceutical drugs

Specific content

The chemical structure of 1-Piperazinecarboxylic acid, 4-[2-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester
The potential applications of 1-Piperazinecarboxylic acid, 4-[2-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester in the pharmaceutical industry
The need for further study and evaluation of its specific properties and potential uses
The need for thorough assessment of its safety and effectiveness before any potential pharmaceutical applications are realized.

Upstream product

• 100-39-0 benzyl bromide 
• 313657-51-1 tert-butyl 4-(2-hydroxyphenyl)piperazine-1-carboxylate 
• 31575-75-4 2-bromophenyl benzyl ether 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 95-56-7 2-hydroxybromobenzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1011-17-2 2-hydroxyphenylpiperazine 

Downstream Products

• 1277167-72-2 C₂₇H₂₄ClFN₄O₂ 
• 1277167-73-3 C₂₂H₂₂ClN₅O₃ 
• 1277168-03-2 C₁₇H₁₉FN₂O 
• 1277168-04-3 C₁₂H₁₇N₃O₂ 
• 313657-51-1 tert-butyl 4-(2-hydroxyphenyl)piperazine-1-carboxylate 
• 96221-84-0 1-(2-(benzyloxy)phenyl)piperazine 

Relevant academic research and scientific papers

THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION

Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. The compounds and compositions can be used to modulate an isocitrate dehydrogenase (IDH) mutant (e.g., IDHIm or IDH2m) having alpha hydroxyl neoactivity

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled hum

Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (Ki = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (Ki = 6600 nM). Sulfonamide 39 (Ki = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (Ki = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (Ki = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.